11 | 18 | 2021

ANGIODYNAMICS

Canaccord Genuity MedTech & Diagnostics Forum 2021

Jim Clemmer, President & CEO
Stephen Trowbridge, EVP & CFO

angiodynamics

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2021. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has included adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results.

MED TECH

Invest for Growth

Thrombus Management

AngioVac Uni-Fuse+

ALPHAVAC

MULTIPURPOSE MECHANICAL ASPIRATION

Peripheral Atherectomy

AURYON

Irreversible Electroporation

NanoKnife

Irreversible Electroporation (IRE)

angiodynamics



MED DEVICE

Maintain Positioning

- Vascular Access Catheters and Accessories
- Diagnostic Catheters, Guidewires and Kits
- Endovenous Laser Treatment
- Microwave & Radiofrequency Tumor Ablation
- Lung Biopsy Safety
- Radiation Treatment Stabilization Balloons

FOCUSED TRANSFORMATION

U.S. Total Addressable Markets



angiodynamics

The planned portfolio additions and new indications are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

VTE Represents 390k Cases Annually

Deep Vein Thrombosis

DVT

A blood clot that forms in a deep vein, usually the leg, groin or arm

+

Pulmonary Embolism

PE

A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply

=

208,000 Iliofemoral Cases[1]

171,000 High-risk & intermediate-risk PE Cases[1]



Stages of Clot

Clot in Transit *(traveling through the heart)*

Clot in Pulmonary Arteries *(PE)*

angiodynamics

1.Plovanic, W. J., & Furlong, C. (2020, June). Inari Medical Biomedical Devices and Services. Canaccord Genuity Capital Markets.
2."Venous Thromboembolism (VTE)." *World Thrombosis Day*. www.worldthrombosisday.org/issue/vte. Illustrations and Images not Produced by AngioDynamics Include: https://www.vascularmedcure.com/disease-background
DVT (Blood Clot In the Leg): 7 Warning Signs and Symptoms (emedicinehealth.com)

Venous Thromboembolism

VTE

DVT and PE are collectively referred to as VTE

- ***VTE** Affects up to **900k** Americans each year*
- ***100,000** VTE-Related Deaths in the USA Annually[2]*
- *Roughly 30% of Americans who get a blood clot will have a reoccurrence in less than 10 years*
- *VTE Costs our US Healthcare system $10 Billion a year*

https://www.cdc.gov/ncbddd/dvt/data.html

The AngioVac Difference

The AngioVac System allows for the **continuous aspiration** of embolic material such as fresh, soft thrombi or vegetation from the venous system

Utilizing a self-expanding, nitinol reinforced **funnel tip**

Simultaneously reinfusing the patient's own filtered blood to limit procedural blood loss



angiodynamics



Individual experience may not be indicative of all procedure results.

THE NEXT GENERATION OF ANGIOVAC

Physician requests for use in DVT drive new product development

ALPHAVAC

MULTIPURPOSE MECHANICAL ASPIRATION

THE NEXT PORTFOLIO INNOVATION

A purpose-built, innovative product leveraging the strengths of the AngioVac cannula technology with *off-circuit* manual aspiration control

Powerful

Proven funnel tip design allows efficient aspiration and compression of large clot burden

Controlled

Designed to allow the end-user command and control of the mechanical aspiration

Versatile

Broadens Thrombus Management portfolio and is designed to provide an intuitive, first-line treatment option without the need for lytics and advanced procedural support

Handle | Control Features



MALE AND FEMALE CONNECTION
Ensures correct connection

DIRECTIONAL LABELS
Cannula | Waste Bag

ANGLED EXIT
Prevents large thrombus clog

SPACER
Allows sterile blood path and confirms plunger passes shelf-life constraints

ROBUST DESIGN
Enables smooth pulls with contemporary design

SYRINGE BARREL

VOLUME LIMITING SWITCH
Intuitive location | Multiple glove sizes

DURABLE LABELS
Visible in low light environments

VACUUM LOCK
Controlled, single-hand design

ANGLED HILT
Easy access to vacuum lock

TEXTURED GRIP
Enhances grip control

F18$^{85°}$ Cannula | Simple Design. Powerful Features.

OBTURATOR

Lubricious Shaft Material
Easy delivery through tortuous anatomy

Tapered Distal Tip
Enhanced navigation and safety

SHEATH

Quarter Turn Valve
Locks tip angle in place

Side Arm Flush Port
Remove air between sheath and cannula

Radiopaque Tapered Soft Tip
Enhanced visibility
Atraumatic transition to obturator



Funnel Shaped Handle
Guided device insertion

Hemostasis Valve
Prevents blood loss during device exchange

CANNULA

Handle Alignment Rib
Indicates cannula curve

Triple Durometer Braided Shaft
Stiffness for powerful push, terminates with a more flexible atraumatic distal end with 1:1 torque

Nitinol Reinforced Funnel Tip
Reliable clot entrapment and removal

Quick Connect

85° Cannula Bend
Enhanced direct-ability



AlphaVac F18^{85} is not cleared by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the FDA. The device is not currently being marketed, nor is it available for sale in any country.

ADDRESSABLE MARKET

Thrombus Procedures by Location



PE
167K Patients
$1.6B TAM

Right Heart/Atrium
97K Patients
$77M TAM

IVC/SVC – Caval DVT
20K Patients
$360M TAM

Ilio-Femoral – DVT
246K Patients
$700M TAM

Popliteal – DVT
95K Patients
$300M TAM

RESTORATIVE FLOW THERAPIES

AlphaVac F18^{85} and F13^{10} are not cleared by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the FDA. The device is not currently being marketed, nor is it available for sale in any country. AlphaVac and AngioVac are not indicated for PE.

Deliberate Attention to Key Technology Elements

	AngioVac F22^{20}	AngioVac F22^{180}	AlphaVac F18^{85}	AlphaVac F13^{10}	AlphaVac F18^{85} PE
Funnel Tip Opening FR Size	42FR	42FR	33FR	~16FR	33FR
Cannula Angle Degree	20°	180°	85°	10°	85°
Cannula FR Size	22FR *Cannula* 25FR *Sheath*	22FR *Cannula* 25FR *Sheath*	18FR *Cannula* 22FR *Sheath*	~13FR *Cannula* ~16FR *Sheath*	18FR *Cannula* 22FR *Sheath*
Modality Type			*Shapes, Sizes and Angles will be available in both on/off circuit options (AlphaVac/AngioVac)*		
Availability	FY22 Q2/3	FY22 Q2/3	FY22 Q3*	FY23 Q4*	FY24 Q4*

THROMBUS MANAGEMENT

Planned Portfolio Additions & U.S. Addressable Markets Expansion



angiodynamics

The planned portfolio additions are not guarantees of future performance and are subject to risks and uncertainties, including clearance by the FDA. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

Purpose Built, Comprehensive, Thrombus Portfolio

$1.3B[1]

AngioVac

Continuous Aspiration with Simultaneous Reinfusion

F22^20 | F22^180 | F18^85 | 18^85 PE | F13^10

ALPHAVAC

Multi-purpose Mechanical/Manual Aspiration

F22^20 | F22^180 | F18^85 | 18^85 PE | F13^10

Uni-Fuse+

Catheter Directed Thrombolysis with PE Indication

PERIPHERAL ATHERECTOMY

US Addressable Markets & Competitive Landscape

- Over 8 Million[2] Americans Suffer from PAD
- Over 150,000 Limbs[4] are Lost Every Year because of PAD
- 50% Mortality Rate[4] Associated with PAD after Limb Loss

2021 Served Market



3. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millenium Research Group, Inc.

4. https://www.cookmedical.com/peripheral-intervention/10-facts-about-peripheral-arterial-disease/

AURYON



2.35 mm
Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR)

2.0 mm
Aspiration capability and indicated for Peripheral Atherectomy and ISR

1.5 mm
Indicated for Peripheral Atherectomy

0.9 mm
Indicated for Peripheral Atherectomy

Why wavelength matters

Each type of tissue interacts differently with a given wavelength

The Auryon System produces a photon energy of 3.5 eV, which is low enough to be nonreactive to vessel endothelium, but high enough to vaporize calcium. [6,7]

Why pulse width and amplitude matter

Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs

The Auryon System has a pulse width of 10 to 25 ns, ensuring enough power to target the lesion and spare the vessel. [5]

angiodynamics

5. Auryon. Instructions for use. AngioDynamics; 2019. **6**. Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287.
7. Spectranetics Corporation. CVX-300 Excimer Laser System: Operator's Manual. Version 28. 2019:1-56.

INNOVATION DOCTORS NEED

Expands treatment options and help preserve patient's quality of life

PROBE PLACEMENT

NanoKnife can be confidently used in all segments of an organ.[10,11]

DECELLULARIZATION

Destroys targeted tissue with precise treatment margins.[10,11]

NON-THERMAL

Spares vital structures by retaining the structural integrity of tissue.[12,13]

REVASCULARIZATION

Facilitates functional tissue regeneration post-ablation.[12,13]

10. Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. (2010);4(SUPPL. 1):99–104. doi: 10.5009/gnl.2010.4.S1.S99
11. Guidance for Selection of NanoKnife Probe Array Configuration and Ablation parameters for the Treatment of Stage III Pancreatic Cancer.
12. Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060.
13. Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412.

THE NANOKNIFE SYSTEM

Estimated # of U.S. Patients Diagnosed in 2021[9]



angiodynamics



8. Interventional Oncology Devices Medtech 360 Market Analysis US 2
(2016, December). Millennium Research Group, Inc.
9. "Cancer Facts & Figures 2021." American Cancer Society.
www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.

FOCAL THERAPY

U.S. Served and Target Markets



angiodynamics

14. D"Cancer Facts & Figures 2021." American Cancer Society. www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.
15. Definitive Healthcare All-Payor Hospital Outpatient Volume by CPT Code, 02/05/2021
16. Parry MG, Cowling TE, Sujenthiran A, et al. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Medicine. 2020;18(1). doi:10.1186/s12916-020-01588-9

PRESERVE Prostate IDE

SUO-CTC is a clinical research investigator network of 500+ members from more than 250 clinical sites in the US and Canada.

37	SUO-CTC US sites responded to Call for Sites
Up to 20	Sites to be selected, focused on geographic and demographic diversity, high-volume focal therapy institutions
100	Intermediate-risk patients enrolled through one year follow up

Primary endpoint: Rate of negative in-field biopsy at 1 year

angiodynamics

FINANCIALS

First Quarter Highlights

Financial Performance

$ in thousands (except per share data)

	Q1 FY2022	Q1 FY2021	YOY Change
Revenue	$76,971	$70,216	9.6%
Gross Margin	52.1%	50.9%	120 bps
Net Loss	($6,972)	($4,268)	($2,704)
GAAP EPS	($0.18)	($0.11)	($0.07)
Adjusted EPS	($0.02)	$0.02	($0.04)
Adjusted EBITDA	$3,570	$4,466	($896)

To view the Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS visit: investors.angiodynamics.com.

First Quarter FY2022 Results (unaudited)

$ in thousands (except per share data)	Q1 FY2022	Q1 FY2021	Change
Revenue	**$76,971**	**$70,216**	**9.6%**
Med Tech	$17,619	$10,486	68.0%
Med Device	$59,352	$59,730	(0.6%)
Endovascular Therapies	$38,058	$29,857	27.5%
Vascular Access	$24,957	$28,105	(11.2)%*
Oncology	$13,956	$12,254	13.9%
United States	$64,464	$54,108	19.1%
International	$12,507	$16,108	(22.4%)
Net Loss	**($6,972)**	**($4,268)**	**($2,704)**
Non-GAAP Adjusted Net Income (Loss)	($887)	$618	($1,505)
GAAP EPS	**($0.18)**	**($0.11)**	**($0.07)**
Non-GAAP Adjusted EPS	($0.02)	$0.02	($0.04)
Gross Margin	**52.1%**	**50.9%**	**120 bps**
Adjusted EBITDA	**$3,570**	**$4,466**	**($896)**

$ in thousands	Q1 FY2022	Q4 FY2021	Change
Cash	$35,472	$48,161	($12,689)
Debt	$25,000	$20,000	$5,000
Net Cash	**$10,472**	**$28,161**	**($17,689)**

* Excluding the impact of the $5.2 million NHS order in the prior year VA was up 9.0%.

angiodynamics

To view the Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS visit: investors.angiodynamics.com.

STRATEGIC TRANSFORMATION

PURSUE LARGER, FASTER GROWING MARKETS

Active portfolio management enables us to compete in larger, faster growing markets relying on technology & innovation to produce measurable patient outcomes

DEPLOY FOCUSED RESOURCE DEVELOPMENT

Resource deployment focused in areas that offer better opportunities for success

DRIVE PORTFOLIO TRANSFORMATION

Portfolio transformation & strength driven by R&D, M&A, and Clinical & Regulatory

ATTRACT AND RETAIN TOP TALENT

Strong and innovative portfolio combined with top talent drives value